首页> 外文期刊>Oncology research and treatment. >Non-Urothelial Bladder Cancer: Comparison of Clinicopathological and Prognostic Characteristics in Pure Adenocarcinoma and Non-Bilharzial Squamous Cell Carcinoma of the Bladder
【24h】

Non-Urothelial Bladder Cancer: Comparison of Clinicopathological and Prognostic Characteristics in Pure Adenocarcinoma and Non-Bilharzial Squamous Cell Carcinoma of the Bladder

机译:非尿路上皮膀胱癌:膀胱纯腺癌和非Bilharzial鳞状细胞癌中的临床病理学和预后特征的比较

获取原文
获取原文并翻译 | 示例

摘要

Objectives: The clinicopathological characteristics, treatment modalities, and effects on the prognosis of pure squamous cell carcinoma (SqCC) and adenocarcinoma (AC) were evaluated. Materials and Methods: 86 patients with pure SqCC and AC bladder cancer were evaluated retrospectively. Results: Of the 86 patients, 51 had SqCC and 35 had AC. No differences in clinicopathological characteristics were observed between patients with AC and SqCC, except for the prevalence of T4 disease (28.6% vs. 51.0%, respectively). In multivariate analysis, older age, stage IV disease, and Eastern Cooperative Oncology Group (ECOG) performance status ( 2) were predictive of a poor overall survival (OS). The median OS was significantly longer for stage I-III patients (82.9 months) treated with surgery +/- chemotherapy (CT) +/- radiotherapy (RT) than for those treated with transurethral resection +/- CT +/- RT (24.3 months) (P = 0.007). The median OS of patients with SqCC and AC who were given platinum-based CT for metastasis was 7.7 and 30.3 months, respectively. Conclusions: Advanced age, stage IV disease, and poor ECOG performance status were factors associated with a poor prognosis. Surgery +/- CT +/- RT resulted in significantly better OS, except in stage IV disease. Patients with metastatic AC had better response rates with platinum- based CT. (c) 2018 S. Karger GmbH, Freiburg
机译:目的:评价临床病理特征,治疗方式和对纯鳞状细胞癌(SQCC)和腺癌(AC)预后的影响。材料和方法:回顾性评估86例纯SQCC和AC膀胱癌。结果:86例患者,51例SQCC,35人有AC。在AC和SQCC患者之间没有观察到临床病理特征的差异,除了T4疾病的患病率(分别为28.6%,分别为51.0%)。在多变量分析中,年龄较大的年龄,阶段疾病和东方合作肿瘤组(ECOG)绩效状况(& 2)预测整体生存率差(OS)。阶段I-III患者(82.9个月)的中位OS显着更长,手术+/-化疗(CT)+/-放射疗法(RT),而不是经尿道切除+/-CT +/- RT处理的那些(24.3月份)(p = 0.007)。 SQCC和AC患者的中位OS分别为铂族基于铂的CT进行转移为7.7和30.3个月。结论:晚期,阶段IV病,差的ECOG绩效状况是与预后差相关的因素。除阶段IV疾病外,手术+/- CT +/- R导出明显更好的操作系统。转移性AC的患者与基于铂的CT具有更好的反应率。 (c)2018年S. Karger GmbH,Freiburg

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号